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Abstract
Background: Friedreich ataxia, an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low
levels of frataxin, an essential mitochondrial protein. All Friedreich ataxia patients carry a GAA?TTC repeat expansion in the first
intron of the frataxin gene, either in the homozygous state or in compound heterozygosity with other loss-of-functionmutations.
The GAA expansion inhibits frataxin expression through a heterochromatin-mediated repression mechanism. Histone
modifications that are characteristic of silenced genes in heterochromatic regions occur at expanded alleles in cells from
Friedreich ataxia patients, including increased trimethylation of histone H3 at lysine 9 and hypoacetylation of histones H3 and H4.
Methodology/Principal Findings: By chromatin immunoprecipitation, we detected the same heterochromatin marks in
homozygous mice carrying a (GAA)230 repeat in the first intron of the mouse frataxin gene (KIKI mice). These animals have
decreased frataxin levels and, by microarray analysis, show significant gene expression changes in several tissues. We
treated KIKI mice with a novel histone deacetylase inhibitor, compound 106, which substantially increases frataxin mRNA
levels in cells from Friedreich ataxia individuals. Treatment increased histone H3 and H4 acetylation in chromatin near the
GAA repeat and restored wild-type frataxin levels in the nervous system and heart, as determined by quantitative RT-PCR
and semiquantitative western blot analysis. No toxicity was observed. Furthermore, most of the differentially expressed
genes in KIKI mice reverted towards wild-type levels.
Conclusions/Significance: Lack of acute toxicity, normalization of frataxin levels and of the transcription profile changes
resulting from frataxin deficiency provide strong support to a possible efficacy of this or related compounds in reverting the
pathological process in Friedreich ataxia, a so far incurable neurodegenerative disease.
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Introduction
Friedreich ataxia (FRDA, OMIM 229300) is an inherited
recessive disorder characterized by progressive neurological
disability and heart disease [1]. Onset is usually in childhood,
but it may vary from infancy to adulthood. Atrophy of sensory and
cerebellar pathways causes ataxia, dysarthria, fixation instability,
deep sensory loss and loss of tendon reflexes. Corticospinal
degeneration leads to muscular weakness and extensor plantar
responses. With progression, patients lose the ability to walk and
become dependent for all activities. In some cases, visual loss and
neurosensorial deafness further increase disability. A hypertrophic
cardiomyopathy, present in most cases, may become symptomatic
and even cause premature death. Other common problems
include kyphoscoliosis, pes cavus, and, in 10 % of patients,
diabetes mellitus [1].
FRDA is caused by partial deficiency of the mitochondrial protein
frataxin. Though the function of frataxin is still partly controversial,
there is general agreement that it is involved in cellular iron
homeostasis and that its deficiency results in multiple enzyme
deficits, mitochondrial dysfunction and oxidative damage [2,3].
Frataxin binds ferrous iron through negatively charged amino acids
on its surface [4], it promotes the mitochondrial synthesis of iron-
containing molecules, in particular iron-sulfur clusters (ISCs) [5] and
heme [6], and it controls the ability of iron to perform redox
chemistry [7]. Frataxin deficiency significantly affects ISC synthesis
and results in reduced activities of several enzymes that require ISCs
as prosthetic groups [8]. Frataxin may also have a more general
protective effect against oxidative stress and in determining
antioxidant responses, even in the absence of excess iron.
Complete absence of frataxin is incompatible with life in higher
organisms, as demonstrated by the embryonic lethality observed in
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systemic gene knock-out models [9–12] and by the eventual loss of
cells targeted for frataxin gene deletion in conditional knock-out
models [13]. The human disease is caused by the pathological
hyperexpansion of a GAA?TTC repeat sequence, ranging from
60–1700 repeats, in the first intron of the frataxin (FXN, MIM:
606829, GeneID: 2395) gene that partially suppresses FXN gene
expression [14]. This mutation is present at the homozygous state
in most patients and in compound heterozygosity with a different
loss-of-function mutation in a small minority of cases (about 5%).
In FRDA patients, frataxin amounts vary between 5% and 30% of
those of normal individuals, and are little more than 50% of
normal in heterozygous FRDA carriers, who have no sign of
disease [14–16]. These findings suggest that restoring FXN gene
expression in FRDA patients to heterozygote levels may
substantially slow the course of the disease. In order to develop
treatments to reduce or eliminate FXN transcriptional silencing, it
is necessary to understand the underlying mechanisms. In vitro and
in bacterial plasmids, pathological lengths of GAA repeats adopt a
non-B, triple helical DNA structure that blocks and sequesters the
advancing RNA polymerase [17–20]. The same repeats, when
linked to a reporter gene in transgenic mice [21] and in cells from
FRDA patients [22], become associated with transcriptionally
silent heterochromatin. Therefore, decondensing the chromatin
structure at the GAA repeat expansion appears an appealing
target for FRDA therapeutics. Since deacetylated histones are
generally associated with silent heterochromatin, HDAC inhibitors
(HDACI) have the potential to make heterochromatin revert to an
open, active conformation that allows gene expression [23]. In a
previous study, a substantial increase in frataxin in lymphoblastoid
cells and in primary, non-replicating lymphocytes from FRDA
patients was only obtained when using a specific class of HDACI,
analogs of the compound BML-210 (N1-(2-aminophenyl)-N8-
phenyloctanediamide), including the highly active compound 4b
(N1-(2-aminophenyl)-N7-phenylheptanediamide) [22]. 4b and re-
lated compounds raised frataxin levels to and above those of
carriers, under conditions without apparent toxicity. The increase
in FXN transcription is accompanied by increased acetylation of
histone H3 at lysine14 (H3K14), as well as at H4K5 and H4K12
near the GAA repeat [22].
As a further step to evaluate these drugs as potential FRDA
therapeutics, we have now investigated the efficacy and acute toxicity
of a compound from this novel family of HDACI in a FRDA mouse
model. Our data indicate that in a mouse model that carries
expanded GAA repeats in the endogenous frataxin (fxn) gene, a
member of this class of HDACI is able to restore frataxin levels and
the gene expression profile to those of wild-type mice.
Results
fxn (GAA)230/(GAA)230 (KIKI) mice recapitulate the genetic
and epigenetic features of FRDA and have an altered
gene expression profile as a consequence of mild frataxin
deficiency
We previously generated a knock-in mouse carrying a (GAA)230
repeat in the first intron of the endogenous frataxin gene (fxn) [24],
and we showed that homozyogous fxn(GAA)230/(GAA)230 (KIKI)
mice have mildly but significantly lower frataxin levels than wild-
type (WT) animals with the same strain background (C57Bl/6), as
determined by densitometry of western blots and semiquantitave
RT-PCR [24]. In the present study, we confirmed by quantitative
real-time RT-PCR the reduction in frataxin mRNA in KIKI
brain, cerebellum and heart (Figure 1A). We then investigated the
histone H3 and H4 post-translational modifications in chromatin
near the GAA repeat by chromatin immunoprecipitation (ChIP).
We found changes that correspond to those occurring in cells from
FRDA patients [22], though they are quantitatively less marked, as
expected given the relatively short GAA repeats in KIKI mice
compared to a typical FRDA patient (Figure 1B). Taken together,
these findings validate the KIKI mouse as a model for the frataxin
transcriptional silencing and corresponding epigenetic changes as
observed in FRDA.
Though KIKI frataxin levels are not expected to cause an overt
phenotype, as they even exceed the 50% expression found in
asymptomatic gene knockout heterozygous mice [10], we
investigated whether they cause changes in gene expression
profiles in tissues that are affected in FRDA, such as the central
nervous system (CNS) and heart. For this purpose, we performed
high-density microarray studies to compare the global gene
expression profile in the brain (cerebral hemispheres), cerebellum
and heart of KIKI mice to wild-type mice. 615 unique genes were
found to be differentially expressed in KIKI vs WT samples at
P,0.005 (Figure 1C). Fold changes were small in amplitude
(within 2-fold changes). Complete gene lists are in Table S1 and
have been deposited in the GEO database (accession number
GSE10745). KIKI mice therefore have a clear, reproducible
molecular phenotype. The biological relevance of this phenotype is
further indicated by the significant overlap with gene expression
changes found in FRDA patients’ lymphocytes and in more
severely frataxin-deficient fxn(GAA)230/- (KIKO) mice [25,26]. In
the absence of any detectable pathology, and therefore of non-
specific changes due to cell atrophy and degeneration, these gene
expression modifications are likely to represent a direct compen-
satory or stress-related response to lower levels of frataxin that can
be used as a biomarker to evaluate the effectiveness of attempts to
restore normal frataxin levels.
Effects of compound 106 on frataxin levels and histone
modifications in KIKI mice
Compound 106 (N1-(2-aminophenyl)-N7-p-tolylheptanediamide;
see Figure 2A for structure and Methods S1 for synthetic
methods), a derivative of 4b, was found to be highly active in
increasing histone acetylation in cell culture and FXN mRNA
levels in primary lymphocytes from FRDA patients (Figure 2, B
and C). Moreover, the parent compound 4b and other derivatives
increased histone acetylation in the brains of WT mice when
injected subcutaneously (data not shown). Based on these results,
we next examined whether treatment of KIKI mice with 106
resulted in increased histone acetylation in the brain, and we
estimated the duration of this effect. After three doses of 150 mg/
Kg of 106 given subcutaneously once a day for three consecutive
days, increased histone acetylation was evident in the brain at least
for 24 hours after the last injection, but had completely
disappeared after a week (Figure 3A). Next, a group of 12 KIKI
mice received subcutaneous injections of 150 mg/kg of 106 every
24 hours for three consecutive days to evaluate the effects of the
compound on fxn mRNA and frataxin protein levels and on
histone modifications near the GAA repeat. No apparent animal
toxicity was associated with 106 treatment. Tissues (brain,
cerebellum, and heart) were processed for RNA and protein
extraction and for chromatin immunoprecipitation (ChIP) exper-
iments.
Fxn mRNA, quantified by quantitative real-time RT-PCR, was
significantly lower in the brain, cerebellum and heart of vehicle-
treated KIKI mice than in similarly treated WT animals.
Treatment with 106 increased KIKI fxn mRNA to levels that
did not significantly differ from WT (Figure 3B), thus demon-
strating correction of fxn deciciency in these animals. We
confirmed that increased fxn mRNA levels resulted in higher
HDAC Inhibitors in FRDA
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Figure 1. Frataxin mRNA levels and histone modifications on chromatin in the first intron of the frataxin gene in KIKI and WT mice.
(A) We determined frataxin mRNA levels by quantitative real-time RT-PCR in brain, heart and cerebellum of 8 weeks old WT and KIKI mice (n = 8). All
values are normalized to RER1 and b2m mRNA levels and are relative to WT brain, set to 100. Error bars are SD. Data were generated in two
independent experiments. (** P,0.001). (B) Levels of H4K5, H4K8, H4K16, H3K14 acetylation and of H3K9 trimethylation in KIKI and WT mice brains
(n = 8). We performed ChIP experiments with antibodies for murine histones H3 and H4 that carry each of the indicated modifications. We used
primer pairs from the first intron of the mouse frataxin gene just upstream of the point of insertion of the GAA repeat in KIKI mice. Relative recovery,
determined by quantitative real-time RT-PCR, is expressed in relation to GAPDH and the recovery in samples from WT animals is set to 100 for each
antibody. Error bars are SEM. of four independent immunoprecipitations, each quantified in triplicate. (C) Histogram showing the number of genes
differentially expressed in KIKI mouse brain (cerebral hemispheres), cerebellum and heart compared to WT mice. Genes with increased expression in
KIKI mice are in red, genes with decresed expression in KIKI mice are in green. Only genes showing changes at P,0.005 are counted.
doi:10.1371/journal.pone.0001958.g001
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frataxin protein level by western blotting (Figure 3, C and D).
Treatment with 106 did not result in increased fxn mRNA levels in
WT animals (Figure S1), indicating that its effect was due to
removal of the inhibition caused by the GAA expansion.
We then checked whether in KIKI mice, as observed in
lymphocytes from FRDA patients, 106 treatment was accompa-
nied by changes in histone modifications in chromatin near the
GAA repeat that could lead to a more transcription-permissive
state. After HDACI treatment, trimethylation of H3K9 remained
high, as previously observed in FRDA cells [24], but acetylation
levels increased at all other explored positions in histones H3 and
H4 (Figure 3E).
Effect of HDACI 106 on the global gene expression
profile in the brain, cerebellum and heart of WT and KIKI
mice
Figure 4A shows the effects of treatment with 106 on gene
expression in the brain, cerebellum and heart of KIKI and WT
mice evaluated by high-density microarray analysis [27]. Com-
plete gene lists are in Table S1 and are available from the GEO
database (accession number GSE10745). 670 probes (655 unique
genes) were affected by 106 treatment in either tissue in either
strain, showing small (less than two-fold) changes in expression.
The relatively limited overall effect of 106 on expression profiles
and the lack of major changes in apoptosis or tumorigenesis-
related genes suggest that severe adverse effect from this
compound are unlikely, at least at the utilized dosage.
Despite some overlap, likely to reflect the general effects of this
HDACI on gene expression, 106-induced modifications of
expression profiles significantly differed between WT and KIKI
mice. The most striking finding concerned the set of genes that
were differentially expressed in untreated KIKI vs. WT mice.
Most of these genes (67% in brain, 84% in cerebellum, 67% in
heart) showed coordinate changes towards normal levels after 106
treatment (Figure 4B). In a subset of these genes (34% in brain,
23% in cerebellum, 60% in heart at P,0.005; Table S1 and
Figure 4C), these changes reached statistical significance. In WT
mice, the same genes showed no significant change or minor
changes in either direction. Therefore, treatment with 106
modified the global gene expression profile in KIKI animals to
resemble the WT profile.
Discussion
In the present study we have demonstrated the in vivo feasibility
of a therapeutic approach to activate the FXN gene in a mouse
model that recapitulates the genetic and epigenetic features of
FRDA. Previous work has shown that FXN silencing in FRDA is
likely to be the consequence of chromatin changes induced by the
expanded intronic GAA repeat. Post-translational modifications of
histone tails are thought to form a code, called the histone code
[28], that affect gene expression by providing binding sites for
proteins involved in controlling chromatin condensation and
transcription. Increased trimethylation at H3K9 and decreased
acetylation at H3K14, H4K5, H4K8, H4K12 and H4K16
constitute hallmarks of silent heterochromatin and are found
immediately upstream and downstream of the GAA repat
expansion in cells from FRDA patients [22]. KIKI mice have
similar changes, indicating that they are a suitable model for in vivo
testing of treatments to alter histone modifications that may restore
frataxin levels in FRDA.We chose a novel HDACI, compound 106,
for testing in the animal model. 106 has been developed as an analog
of the compound BML-210, the first HDACI shown to be effective
in increasing acetylation levels at critical histone residues near the
GAA repeat and in restoring frataxin levels in cultured cells from
FRDA patients [22]. In contrast, other common potent HDACIs,
such as as suberoylanilide hydroxamic acid (SAHA), suberoyl bis-
hydroxamic acid (SBHA), trichostatin A (TSA), and valproic acid
(VPA) do not increase FXN gene expression in cells from FRDA
patients. The molecular basis for why these compounds are
ineffective, as compared to the pimelic diphenylamides, exemplified
by 106, is currently under investigation.
We have established that 106 penetrates the blood-brain barrier
and increases histone acetylation in the brain at a dose that causes
no apparent toxicity in WT C57Bl/6 or in KIKI mice. This
compound was able to restore normal frataxin levels in the central
nervous system and heart of KIKI mice, tissues that are relevant
Figure 2. Effects of HDACI 106 on histone acetylation and FXN mRNA. (A) Structure of HDACI 106. (B) Histone H4 acetylation in normal
fibroblast cells (GM08333 Coriell Cell Repositories, Camden, NJ) was measured by Western blot of total cell lysate after 24 hr incubation with
indicated compounds. 9b (N1-(2-methoxyphenyl)-N7-phenylheptanediamide) has been described [22]. Compounds were dissolved in DMSO prior to
addition to cell culture to give the final concentration indicated above at 0.1% DMSO. (C) FXN mRNA levels were measured in RNA from isolated
PBMCs from carrier/patient pairs (1–3) after a 48 hour incubation with 106 or DMSO (at 0.1%). Quantitative real-time RT-PCR was used to determine
relative FXN levels between each carrier/patient pair using GAPDH as a control housekeeping gene. Error is represented as the standard deviation of
the mean from 3 determinations. Primary lymphocytes were obtained from donor blood from FRDA patients and their carrier relatives (under an
approved Human Subjects Protocol, with appropriate informed consent) as described [22].
doi:10.1371/journal.pone.0001958.g002
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targets as they are involved in FRDA pathology. As no effect on
frataxin levels was observed in similarly treated WT mice, we
conclude that 106 directly interferes with the transcriptional
repression mechanism triggered by the GAA repeat, which is
thought to involve the induction of transcriptionally silent
heterochromatin. Accordingly, the typical histone marks of
heterochromatic regions that are present near the GAA repeat
in KIKI mice were partially removed by treatment with 106. In
particular, acetylation increased with treatment at several lysine
residues in histones H3 and H4, but no decrease in H3K9
trimethylation occurred. We propose that increased acetylation of
H3K14 and of K5, K8 and K16 on H4, results in a more open,
transcription permissive chromatin state despite persisting H3K9
trimethylation, because it interferes with binding of repressive
proteins that recognize the trimethylated H3K9 mark, such as
heterochromatin protein 1 (HP1) [29].
Restoring frataxin expression represents an important step
toward a treatment for FRDA if it is followed by functional
recovery of affected cells. KIKI mice do not show overt pathology
or abnormal behavior, but we identified changes in the overall
gene expression profiles in relevant tissues that constitutes an
observable, reproducible and biologically relevant phenotype as
well as a biomarker to monitor the effectiveness of treatments.
Remarkably, after 106 treatment gene expression profiles showed
a clear trend toward normalization. This phenomenon cannot be
considered a non-specific consequence of HDACI treatment,
because the involved genes were not significantly modified in
treated WT mice, whose frataxin levels also remained stable.
Normalization of the transcription profile changes induced by
lowered frataxin provides strong support to a possible efficacy of
this or related compounds in reverting the pathological process in
FRDA, at least as long as major cell loss has not occurred. Based
on our results, potential therapeutics may be developed for FRDA,
a so far incurable neurodegenerative disease.
Materials and Methods
Animal procedures
GAA knock-in mice were generated and genotyped as described
[24]. Age and gender matched WT littermates were used as
controls. Mice were treated by subcutaneous daily injections with
150 mg/kg of HDACI 106 or its equivalent of vehicle, for 3
Figure 3. Effects of HDAC inhibitor 106 on frataxin mRNA and protein levels and on histone acetylation in KIKI mice. (A) The effect
106 on histone acetylation persists for at least 24 hours in KIKI mice. Mice were sacrificed, then extraction of brain acid-soluble nuclear proteins, SDS-
PAGE, and western blotting with antibodies to total histone H3 and to acetylated histone H3 were performed. Sample in lane a is from the brain of a
106-treated mouse sacrificed after four hours, in lane b is from the brain of a vehicle-treated mouse, in lane c is from the brain of a 106-treated
mouse sacrificed after 24 hours. (B) Frataxin mRNA levels in WT mice and in KIKI mice treated with either vehicle or HDAC inhibitor 106. Frataxin
levels were determined by quantitative real-time RT-PCR relative to RER1 and b2m mRNAs, both unaffected by the HDACI. The WT frataxin mRNA
level in each tissue was set to 100. Brain: n = 12. Cerebellum and Heart: n = 8. Data from 3 separate experiments were pooled and bars indicate SD. (**
P,0.001; * P,0.05). (C) Western blot of frataxin in brain extracts of KIKI mice that had been treated with daily injections of 150 mg/Kg of 106 (lanes
B5–B8) or vehicle (lanes B1–B4) for three days. Mice were sacrified 24 hours after the last injection. Actin was detected for normalization. (D)
Densitometric analysis of the frataxin western blot shown in (C). (E) Levels of H4K5, H4K8, H4K16 and H3K14 acetylation of H3K9 trimethylation in KIKI
mice treated with one subcutaneous injection per day of 150 mg/kg of 106 for 3 consecutive days compared to vehicle-treated KIKI littermates and
WT (n = 6). We performed ChIP experiments with antibodies for murine histones H3 and H4 carrying each modification. Primer pairs corresponded to
the first intron of the mouse frataxin gene just upstream of the point of insertion of the GAA repeat in KIKI mice. Relative recovery, determined by
quantitative real-time PCR, is expressed in relation to GAPDH and the recovery in samples from WT animals is set to 100 for each antibody. Error bars
are SEM of four independent immunoprecipitations, each quantified in triplicate.
doi:10.1371/journal.pone.0001958.g003
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consecutive days. Brain, heart and skeletal muscle were recovered
24 hours after last injection. All procedures respected regulations
and guidelines of the Belgian state and European Union and were
approved by the local ethical committee (CEBEA).
Quantitative real-time RT-PCR
Total RNA from brain stem and/or cerebellum was extracted
by RNeasy Lipid Tissue Mini Kit (Qiagen) as recommended by
the manufacturer. RNA from heart was extracted by RNeasy
Fibrous Tissue Mini Kit (Qiagen). All RNA samples were treated
with RNase-Free DNase Set (Qiagen) and quantified afterwards
by measuring the optical density (NanoDrop ND-1000 Spectro-
photometer, NanoDrop Technologies). Quality and purity of some
samples were analyzed by gel electrophoresis on RNA assay chips
(Experion System and StdSens analysis kit, BioRad Laboratories).
We performed one step quantitative real-time PCR PCR using
MultiScribe Reverse Transcriptase with Power SYBR Green (both
from Applied Biosystems) on the ABI 7500 Fast Real Time PCR
System (Applied Biosystems). Primers used for Fxn were 59-
CCTGGCCGAGTTCTTTGAAG-39 and 59- GCCAGATTTG-
CTTGTTTGG-39. RNA was standardized relative to RER1 and
H2m (b2 microglobulin), mRNA using qBase 1.3.4 (Jan Hellemans
& Jo Vandesompele). Data are normalized to the Fxn mRNA level
in WT mice ( = 100%).
Microarray
Three tissues were studied (brain, cerebellum, heart) in 4
biological replicates, two genotypes (KIKI and WT), and two
treatments (106 and vehicle), for a total of 48 microarrays. Total
RNA (200 ng) was amplified, biotinylated and hybridized on
Illumina Mouse v1.1 Expression arrays as per manufacturer’s
protocol. Raw data was log transformed and checked for outliers.
Inter-array Pearson correlation and clustering based on variance
were used as quality-control measures. Quantile normalization
was used, and analysis of differential expression was performed
using a linear model fitting [27], at a threshold of P,0.005 for
statistical significance. Briefly, a linear model was fitted across the
dataset, contrasts of interest were extracted, and differentially
expressed genes for each contrast were selected using an empirical
Bayes test statistic[27]. Differentially expressed genes were
classified according to gene ontology, using Bioconductor packages
and online tools (DAVID/EASE, http://david.niaid.nih.gov/
Figure 4. Effect of HDACI 106 on global gene expression profiles in the brain, cerebellum and heart of KIKI mice. (A) 670 probes (655
unique genes) in total were affected by drug treatment in either tissue in either strain. A few drug-responsive genes were shared between the two
strains. Quantification of the number of genes (among the 615 KIKI-related) that go in opposite direction after drug treatment show that 70–85%
genes change but only in KIKI samples. In a subset of genes (mostly in cerebellum) this difference was statistically significant at P,0.005. (B)
Heatmaps representing the gene expression profiling before and after treatment with 106 in brain (left), cerebellum (center) and heart (right) of KIKI
mice (four replicates per condition). Fold changes of the genes differentially expressed in KIKI vs. WT (brain = 61, cerebellum=318, and heart = 182
genes at P,0.005) are depicted before treatment (KIKI vs. WT, grey bars on the top) and after treatment (KIKI treated vs. KIKI untreated, blue bars on
the top). Shades of red represent upregulation, shades of green downregulation. Genes and samples are clustered by similarity. (C) Most genes (67%
in brain, 84% in cerebellum, 67% in heart) show coordinate changes towards normal levels after treatment. In a subset of these genes (34% in brain,
23% in cerebellum, 60% in heart) these changes reach statistical significance.
doi:10.1371/journal.pone.0001958.g004
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david/ease.htm). Pathway analysis was carried out using Ingenuity
Pathway Analysis (Ingenuity Systems, www.ingenuity.com).
Western blot analysis
Tissues were homogenized in T-PER tissue protein extraction
reagent (Pierce) for total proteins extraction. Histones were
purified by acid extraction as described in the protocols from
Upstate. Primary antibodies were diluted in Odyssey blocking
buffer (Li-Cor) for frataxin (Chemicon) and actin (Sigma) or in
PBS for total and acetylated histones antibodies (Upstate). Infrared
dye conjugated secondary antibodies (anti-rabbit IRdye800Cw
and anti-mouse IRdye680 from Li-Cor) were used to detect and
quantify the signal of frataxin/actin using a Li-Cor Odyssey
imaging system. Horseradish Peroxidase (HRP) - conjugated
secondary antibodies (Santa Cruz Biotechnology) were used to
detect the signal of total and acetylated histones by chemilumi-
nescence.
Chromatin immunoprecipitation
ChIP was performed as described previously [30]. We adapted
the technique for use on fresh brain tissue and were able to test 3
different residues per one hemisphere. For each immunoprecip-
itation, lysate was incubated with one of the following antibodies
(Anti-acetyl-Histone H3 (Lys14): Upstate Biotechnology 07-353;
Anti-acetyl-Histone H4 (Lys5): Upstate 07-327; Anti-Histone H4
(acetyl K8): Abcam ab-1760; Anti-acetyl-Histone H4 (Lys16):
Upstate 07-329; Anti-trimethyl-Histone H3 (Lys9): Upstate 07-
442; Normal Rabbit IgG: Upstate 12-370. Immunoprecipitated
samples were quantified by real-time PCR following the standard
curve method. Primers used for the region upstream intronic GAA
repeats of Fxn were 59- ACGACAAAGTCTCCCACAGG-39 and




Data are presented as mean6s.d. or s.e.m., or as percentages.
The significance of the difference between groups was evaluated
with the Student’s t-test. P,0.05 was considered significant. (*
P,0.05 unless otherwise noted).
Supporting Information
Figure S1 Effect of HDACI 106 on frataxin mRNA levels in
WT C56Bl6 mice. Mice were treated with either vehicle (n = 7) or
HDAC inhibitor 106 (n= 7). Frataxin mRNA levels were
determined in brain (hemispheres), cerebellum and heart by
quantitative real-time RT-PCR relative to RER1 and b 2m
mRNAs, both unaffected by the HDACI. In each tissue, the
frataxin mRNA level in vehicle-treated animals was set to 100. No
changes were observed after 106 treatment.
Found at: doi:10.1371/journal.pone.0001958.s001 (0.04 MB TIF)
Methods S1 Supplemental synthetic methods for compound
106.
Found at: doi:10.1371/journal.pone.0001958.s002 (0.02 MB
DOC)
Table S1 Microarray data
Found at: doi:10.1371/journal.pone.0001958.s003 (15.57 MB
XLS)
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